Published in Law and Health Weekly, June 26th, 2004
Safety data were presented by Richard Kuntz, M.D., associate professor at Harvard Medical Shool, at the Paris Course on Revascularization.
The Endeavor II trial includes 1,200 patients enrolled at more than 70 hospitals throughout Europe, the Middle East and Asia Pacific. The primary endpoint of the study is target vessel failure (TVF) at nine months. The other co-Principal investigators on the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.